Alpha 1 Antitrypsin Deficiency Aatd clinical trials

Explore recruiting alpha 1 antitrypsin deficiency aatd clinical trials.

Recruiting alpha 1 antitrypsin deficiency aatd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alpha 1 Antitrypsin Deficiency Aatd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants with AATD Pi*ZZ on WVE-006 (RestorAATion-2)

Finland, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, Single-Arm, Open-Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

Spain, Sweden, Denmark, Poland, Ireland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Double-blind, Randomized, Active-control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and safety of SAR447537 (INBRX-101) Compared to Plasma Derived Apha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

Denmark, Sweden, Ireland, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety and clinical parameter assessment of a 12-week home self-infusion therapy with Prolastin® in patients with severe alpha-1-antitrypsin (AATD) deficiency. The “Sunshine Study”

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1/2 Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-3001 in Participants with Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease

Ireland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

TSRA196-AAT-201: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency

Ireland, Sweden, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Alpha 1 Antitrypsin Deficiency Aatd trials by city

Alpha 1 Antitrypsin Deficiency Aatd in Toronto Alpha 1 Antitrypsin Deficiency Aatd in Vancouver Alpha 1 Antitrypsin Deficiency Aatd in Montreal Alpha 1 Antitrypsin Deficiency Aatd in Calgary Alpha 1 Antitrypsin Deficiency Aatd in Edmonton Alpha 1 Antitrypsin Deficiency Aatd in Ottawa Alpha 1 Antitrypsin Deficiency Aatd in Winnipeg Alpha 1 Antitrypsin Deficiency Aatd in Quebec City Alpha 1 Antitrypsin Deficiency Aatd in Hamilton Alpha 1 Antitrypsin Deficiency Aatd in Kitchener Alpha 1 Antitrypsin Deficiency Aatd in London Alpha 1 Antitrypsin Deficiency Aatd in Halifax Alpha 1 Antitrypsin Deficiency Aatd in New York Alpha 1 Antitrypsin Deficiency Aatd in Los Angeles Alpha 1 Antitrypsin Deficiency Aatd in Chicago Alpha 1 Antitrypsin Deficiency Aatd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease